London · Delayed Price · Currency is GBP · Price in GBX Roquefort Therapeutics Statistics
Total Valuation
LON:ROQ has a market cap or net worth of GBP 2.91 million. The enterprise value is 3.11 million.
| Market Cap | 2.91M |
| Enterprise Value | 3.11M |
Important Dates
The next estimated earnings date is Monday, December 29, 2025.
| Earnings Date | Dec 29, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
LON:ROQ has 157.44 million shares outstanding. The number of shares has increased by 4.18% in one year.
| Current Share Class | 157.44M |
| Shares Outstanding | 157.44M |
| Shares Change (YoY) | +4.18% |
| Shares Change (QoQ) | +12.76% |
| Owned by Insiders (%) | 30.23% |
| Owned by Institutions (%) | 47.66% |
| Float | 99.93M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 0.61 |
| P/TBV Ratio | 3.27 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -3.53 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -4.82 |
Financial Position
The company has a current ratio of 2.80, with a Debt / Equity ratio of 0.08.
| Current Ratio | 2.80 |
| Quick Ratio | 0.34 |
| Debt / Equity | 0.08 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.59 |
| Interest Coverage | -17.40 |
Financial Efficiency
Return on equity (ROE) is -18.23% and return on invested capital (ROIC) is -10.91%.
| Return on Equity (ROE) | -18.23% |
| Return on Assets (ROA) | -9.93% |
| Return on Invested Capital (ROIC) | -10.91% |
| Return on Capital Employed (ROCE) | -18.51% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -126,064 |
| Employee Count | 7 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -161,371 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -49.32% in the last 52 weeks. The beta is -0.43, so LON:ROQ's price volatility has been lower than the market average.
| Beta (5Y) | -0.43 |
| 52-Week Price Change | -49.32% |
| 50-Day Moving Average | 1.86 |
| 200-Day Moving Average | 1.95 |
| Relative Strength Index (RSI) | 45.56 |
| Average Volume (20 Days) | 1,710,783 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -932,135 |
| Pretax Income | -1.04M |
| Net Income | -882,451 |
| EBITDA | -926,731 |
| EBIT | -932,135 |
| Earnings Per Share (EPS) | -0.01 |
Balance Sheet
The company has 182,923 in cash and 383,650 in debt, giving a net cash position of -200,727 or -0.00 per share.
| Cash & Cash Equivalents | 182,923 |
| Total Debt | 383,650 |
| Net Cash | -200,727 |
| Net Cash Per Share | -0.00 |
| Equity (Book Value) | 4.75M |
| Book Value Per Share | 0.03 |
| Working Capital | 1.13M |
Cash Flow
In the last 12 months, operating cash flow was -588,753 and capital expenditures -56,865, giving a free cash flow of -645,618.
| Operating Cash Flow | -588,753 |
| Capital Expenditures | -56,865 |
| Free Cash Flow | -645,618 |
| FCF Per Share | -0.00 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
LON:ROQ does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -4.18% |
| Shareholder Yield | -4.18% |
| Earnings Yield | -30.30% |
| FCF Yield | -22.17% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |